Navigation Links
Entry of Biogenerics and Decreasing Use of Amgen's Epogen and Johnson & Johnson's Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
Date:10/29/2007

Upheaval is Forecasted for the Markets of Five Chemotherapy Side Effect

Indications, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chemotherapy-induced anemia will decline by $2.8 billion over the next decade owing to the entry of several biogeneric products and decreasing use of erythropoiesis-stimulating proteins, including Amgen's Epogen and Johnson & Johnson's Procrit.

The new Pharmacor report entitled Managing the Side Effects of Chemotherapy finds that biogeneric erosion combined with emerging safety concerns and an increasingly restrictive reimbursement landscape for erythropoiesis-stimulating proteins will cause the chemotherapy-induced anemia market to decline from $4.5 billion in 2006 to $1.7 billion in 2016. The report also finds that the chemotherapy-induced neutropenia market will decrease $1 billion by 2016 because of the entry of biogeneric versions of Amgen's Neupogen in 2008 in Europe and in 2013 in the United States.

Sales for the most common side effects of chemotherapy-anemia, neutropenia, thrombocytopenia, chemotherapy-induced nausea and vomiting, and oral mucositis-totaled more than $8 billion in 2006 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. According to the report, the market is dominated by therapies that manage anemia and neutropenia effectively for most patients, but considerable opportunity remains for drugs that address thrombocytopenia and oral mucositis, indications characterized by a lack of effective therapies.

"There will be upheaval in the markets for all five of the indications we looked at," said Ramya Kollipara, Ph.D., analyst at Decision Resources. "The decline in drug-treatment rates and the introduction of biogenerics will substantially constrain the market for anemia therapies through 2016, causing the value of the market to fall by nearly a third. Biogeneric erosion will also have a significant impact on the market for neutropenia therapies, and the introduction of novel emerging therapies will have a dramatic impact on the market for anti-thrombocytopenia agents as well."

The chemotherapy-induced nausea and vomiting market will see patent expiries of multiple agents that are thoroughly ingrained in physician treatment algorithms. For oral mucositis, the only available agent, Amgen's Kepivance, is approved only for the prevention of oral mucositis in patients receiving stem cell transplants, but increasing treatment rates and the launch of the first therapy for solid tumor patients will transform the oral mucositis market over the next ten years.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sentry Insurance to add 30 IT jobs in Fox Valley
2. Fiserv plans single entry point for loan processing online
3. Johnson Controls deals for asset-tracking software
4. Johnson Controls adds renewable energy unit
5. Johnson Controls unit lands contract for plug-in hybrid battery
6. Johnson Controls to expand in Europe
7. Johnson Controls partners on car satellite linkup
8. Florida schools employ Johnson Controls technology to stop sex predators
9. Johnson Controls partnership wins new contract
10. Johnson Controls appoints Roell to head EOC
11. Johnson Controls reports record quarterly sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... 2017  BioTech Holdings announced today identification and ... ProCell stem cell therapy prevents limb loss in ... demonstrated that treatment with ProCell resulted in more ... compared to standard bone marrow stem cell administration.  ... reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System ... standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using surface electromyography ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology:
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):